Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 8/20 | 0.37 |
| ▸ | BRD9 | Q9H8M2 | 5/20 | 0.37 |
| ▸ | BPTF | Q12830 | 9/20 | 0.33 |
| ▸ | BRD4 | O60885 | 7/20 | 0.33 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.33 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.33 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12886169 | 0.79 | — | — | |
| SCHEMBL5262357 | 0.78 | — | — | |
| SCHEMBL7966443 | 0.75 | — | — | |
| SCHEMBL5262362 | 0.74 | — | — | |
| SCHEMBL28181371 | 0.74 | — | — | |
| SCHEMBL8282652 | 0.67 | KAT2B (0.55) | KAT2BBRD9BPTFBRD4KAT2A | |
| SCHEMBL21737183 | 0.66 | — | — | |
| SCHEMBL4365342 | 0.65 | — | — | |
| SCHEMBL31549240 | 0.65 | KMT2A (0.40) | ALDH1A1P2RX7 | |
| SCHEMBL27984587 | 0.63 | KAT2B (0.46) | KAT2BBRD9BPTFBRD4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2493886-B1 | HETEROARYL PIPERIDINE AND PIPERAZINE DERIVATES | BAYER CROPSCIENCE AG (DE) | 2014-11-26 | — | — | EP | disclosed |
| US-8501781-B2 | Heteroarylpiperidine and -piperazine derivatives | BAYER CROPSCIENCE AG (DE) | 2013-08-06 | — | — | US | disclosed |
| EP-2493886-A1 | HETEROARYLPIPERIDINE AND -PIPERAZINE DERIVATIVES | Bayer CropScience AG (DE) | 2012-09-05 | — | — | EP | disclosed |
| US-20110306620-A1 | Heteroarylpiperidine And-Piperazine Derivatives | BAYER CROPSCIENCE AG (DE) | 2011-12-15 | — | — | US | disclosed |
| WO-2011051244-A1 | HETEROARYLPIPERIDINE AND -PIPERAZINE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306620-A1 | Heteroarylpiperidine And-Piperazine Derivatives | CAT, DPM1, ERG28 | KAT2B 2011/4885BRD9 1690/4885BPTF 3643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.